Investigational New Drugs

, Volume 19, Issue 2, pp 171–177

Body Surface Area as a Determinant of Pharmacokinetics and Drug Dosing

  • Michael Sawyer
  • Mark J. Ratain

DOI: 10.1023/A:1010639201787

Cite this article as:
Sawyer, M. & Ratain, M.J. Invest New Drugs (2001) 19: 171. doi:10.1023/A:1010639201787


Body surface area (BSA) was introduced intomedical oncology in order to derive a safestarting dose for phase I studies ofanticancer drugs from preclinical animaltoxicology data. It is not clear however,as to why dosing by BSA was extended to theroutine dosing of antineoplastic agents.Several formulas exist to estimate BSA, butthe formula derived by DuBois and DuBois isthe one used in adult medical oncology. This formula was derived based on data fromonly nine patients; subsequent attempts tovalidate the formula have found the DuBoisformula to either over or underestimate theactual determined BSA. While cardiacoutput does correlate with BSA, therelationship between BSA and otherphysiologic measures relevant for drugmetabolism and disposition, such as, renaland hepatic function, is weak ornonexistent. Further only epirubicin,etoposide, and carboplatin have beenstudied to determine if dosing by BSA wouldreduce interpatient variability, and noneof these drugs were found to havesignificant relationships between theirpharmacokinetics and BSA. Future clinicaltrials of new agents should not presumethat dosing based on BSA reducesinterpatient variability. Studies shouldexamine the role, if any, BSA has in dosingnew chemotherapeutic agents in initialphase I studies.

body surface area dosage phase I 

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • Michael Sawyer
    • 1
  • Mark J. Ratain
    • 1
  1. 1.Committee on Clinical Pharmacology, Department of Medicine, and Cancer Research CenterThe University of ChicagoChicagoUSA

Personalised recommendations